• Females aged 18-75 years old (both ends inclusive);

• ECOG performance status (PS) 0-1 points;

• Patients with metastatic or locally advanced breast cancer confirmed by histology（ER positive, HER2 positive/negative，or triple negative breast cancer）.

• Tumor tissue samples must be provided for detection of tumor markers;

• Menopausal state;

• Disease progression confirmed by imaging during or after the last systemic treatment before enrollment;

• There must be at least one measurable extracranial lesion that complies with RECIST v1.1;

• Expected survival \>3 months;

• Good functional level of the organs ;

⁃ Female subjects with childbearing potential must agree to use highly effective contraceptive measures during the study treatment period and within 7 months after the end of the study treatment period; female subjects with childbearing potential must agree to use serum serum within 7 days before study enrollment. The HCG test must be negative and the patient must be non-lactating;

⁃ Voluntarily participate in this clinical trial, be willing and able to comply with clinical visits and research-related procedures, understand the research procedures and have signed informed consent.